Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study
Authors:
- S. Reshwan K. MalaheSMS. Reshwan K. Malahe
- Rogier A.S. HoekRHRogier A.S. Hoek
- Virgil A.S.H. DalmVDVirgil A.S.H. Dalm
- Annoek E.C. BroersABAnnoek E.C. Broers
- Caroline M. Den HoedCHCaroline M. Den Hoed
- Olivier C. ManintveldOMOlivier C. Manintveld
- Carla C. BaanCarla C. Baan
- Charlotte M. van DeuzenCDCharlotte M. van Deuzen
- Grigorios PapageorgiouGPGrigorios Papageorgiou
- Hannelore I. BaxHBHannelore I. Bax
- Jeroen J. Van KampenJKJeroen J. Van Kampen
- Merel E. HellemonsMHMerel E. Hellemons
Preprint
Abstract
Background In the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants. Data on the disease burden of Omicron in immunocompromised patients are lacking. We investigated the clinical characteristics and outcome of a cohort of immunocompromised patients with COVID-19 caused by Omicron. Methods Solid organ transplant recipients, patients on anti-CD20 therapy, and allogenic hematopoietic stem cell transplantation recipients on immunosuppressive therapy infected with the Omicron variant, were included. Patients were contacted regularly until symptom resolution. Clinical characteristics of consenting patients were collected through their electronic patient files. To identify possible risk factors for hospitalization, a univariate logistic analysis was performed. Results A total of 114 consecutive immunocompromised patients were enrolled. Eighty-nine percent had previously received three mRNA vaccinations. While only one patient died, 23 (20%) required hospital admission for a median of 11 days. A low SARS-CoV-2 IgG antibody response (Conclusions While the mortality in immunocompromised patients infected with Omicron was low, hospital admission was frequent and the duration of symptoms often prolonged. Besides vaccination, other interventions are needed to limit the morbidity from COVID-19 in immunocompromised patients. Summary COVID-19-associated morbidity and mortality in immunocompromised patients is unknown for the SARS-CoV-2 Omicron variant. This prospective registry, demonstrated low COVID-19-associated mortality in these vulnerable patients. However, morbidity remained substantial. Other interventions to abate COVID-19 severity are needed.Keywords
All Related Versions
- Published version: Clinical Infectious Diseases, 76 (3), e172.
This publication has 23 references indexed in Scilit:
- Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemicAmerican Journal of Transplantation, 2022
- COVID‐19 in lung transplant recipients: an overview of the Swedish national experienceTransplant International, 2021
- mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialThe Lancet Oncology, 2021
- COVID-19 in Solid Organ Transplantation: Results of the National COVID Cohort CollaborativeTransplantation Direct, 2021
- SARS-CoV-2 Variants in Patients with ImmunosuppressionNew England Journal of Medicine, 2021
- COVID-19 in solid organ transplant recipients: A national cohort study from SwedenAmerican Journal of Transplantation, 2021
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- COVID‐19 in solid organ transplant recipients: a single‐center experienceTransplant International, 2020
- COVID-19 in solid organ transplant recipients: Initial report from the US epicenterAmerican Journal of Transplantation, 2020
- A global clinical measure of fitness and frailty in elderly peopleCanadian Medical Association Journal, 2005